In metastatic colorectal cancer (mCRC), KRAS and BRAF mutations are well-known markers of resistance and poor prognosis in patients receiving anti-epidermal growth factor receptor (EGFR) monoclonal antibodies [13–16]. The gene discussed is BRAF; the disease is metastatic colorectal cancer.